Combined rapamycin and DNA-PK inhibitor treatment was required to suppress AKT phosphorylation and also decreased 4EBP1 phosphorylation in human lung cancer models (89), supporting that DNA-PK is involved in regulating mTOR signaling. The gene discussed is AKT1; the disease is lung cancer.